Its eye/lens development is quite interesting. It is a small company at $126M market cap, even with a 240% gain this year. It was just 26-cents in April and thus it is not one we have paid a lot of attention to. Insiders own 6%. Ventura Holdings owns 36%. It has not much cash, no revenue, losses and negative cash flow. Risks are extremely high here, and it all depends on product development and acceptance. Its focus is the Ocumetics Accommodating Lens, an intraocular lens designed to restore clear vision without the need for eyeglasses and with rapid focus adjustment. If clinical trials succeed and regulatory approval is granted (target: 3.5 years for US FDA), the company projects entry into a US$6.4 billion intraocular lens market by 2030. The first human patient is of course a big milestone, but it does not guarantee anything. OTC is going to need more money, and development always takes more time than expected. Such companies generally have a binary outcome: huge success, or years of dilution and losses. While intriguing, it is too early here for us to endorse.
5i Research Answer: